Login to Your Account



Financings Roundup

Halozyme Raises $40M in Offering; Shares Fall

By Donna Young


Wednesday, June 24, 2009
Halozyme Therapeutics Inc., which is focused on developing and commercializing hyaluronidases targeting the extracellular matrix for endocrinology, oncology and dermatology, raised $40 million by selling 6.15 million shares of its common stock for $6.50 per share. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription